Search details
1.
Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin.
Cell
; 186(17): 3686-3705.e32, 2023 08 17.
Article
in English
| MEDLINE | ID: mdl-37595566
2.
Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy.
Gut
; 73(3): 509-520, 2024 Feb 23.
Article
in English
| MEDLINE | ID: mdl-37770128
3.
Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss.
Cancer Sci
; 113(12): 4311-4326, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36074525
4.
Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.
Gastroenterology
; 160(5): 1741-1754.e16, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33346004
5.
Gab1 in livers with persistent hepatocyte apoptosis has an antiapoptotic effect and reduces chronic liver injury, fibrosis, and tumorigenesis.
Am J Physiol Gastrointest Liver Physiol
; 320(6): G958-G968, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-33787344
6.
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
J Immunother Cancer
; 12(1)2024 01 06.
Article
in English
| MEDLINE | ID: mdl-38184304
7.
Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers.
JHEP Rep
; 6(1): 100959, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38192537
8.
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
Cancer Med
; 13(3): e6912, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38205877
9.
The Gut Microbiome Controls Liver Tumors via the Vagus Nerve.
bioRxiv
; 2024 Jan 25.
Article
in English
| MEDLINE | ID: mdl-38328040
10.
The Microbiome and Liver Cancer.
Cancer J
; 29(2): 57-60, 2023.
Article
in English
| MEDLINE | ID: mdl-36957974
11.
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.
Cancers (Basel)
; 15(2)2023 Jan 11.
Article
in English
| MEDLINE | ID: mdl-36672412
12.
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
J Immunother Cancer
; 11(2)2023 02.
Article
in English
| MEDLINE | ID: mdl-36754451
13.
Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver.
Hepatol Commun
; 6(2): 411-422, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34585534
14.
Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma.
Front Immunol
; 13: 849958, 2022.
Article
in English
| MEDLINE | ID: mdl-35833139
15.
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
Cancers (Basel)
; 14(4)2022 Feb 10.
Article
in English
| MEDLINE | ID: mdl-35205631
16.
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
Cancers (Basel)
; 14(14)2022 Jul 11.
Article
in English
| MEDLINE | ID: mdl-35884434
17.
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Aliment Pharmacol Ther
; 55(4): 422-433, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34812502
18.
White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice.
Cell Mol Gastroenterol Hepatol
; 12(5): 1683-1699, 2021.
Article
in English
| MEDLINE | ID: mdl-34303881
19.
Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration.
Sci Rep
; 11(1): 3363, 2021 02 09.
Article
in English
| MEDLINE | ID: mdl-33564095
20.
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Clin Cancer Res
; 27(4): 1150-1161, 2021 02 15.
Article
in English
| MEDLINE | ID: mdl-33288659